DAX ®12.389,62+0,14%TecDAX ®2.895,31+0,54%Dow Jones27.147,08+0,13%NASDAQ 1007.888,56-0,00%
finanztreff.de

PRESS RELEASE: Torben Sorensen new CEO at curasan AG

| Quelle: Dow Jones Newsw... | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-News: curasan AG / Key word(s): Personnel
Torben Sorensen new CEO at curasan AG

2019-09-12 / 11:43
The issuer is solely responsible for the content of this announcement.

*Torben Sorensen new CEO at curasan AG *

*Kleinostheim, September 12, 2019* - The supervisory board of curasan AG
(DE000A2YPGM4) today has resolved to appoint Mr. Torben Sorensen as the new
CEO of the company as of September 16, 2019 until the end of 31 December
2020.

Torben Sorensen will succeed Michael Schlenk, whose contract anyway expires
on September 30, 2019, and whose request for early resignation effective as
of the end of September 15, 2019 has been accepted by the Supervisory Board
today as well.

Torben Sorensen is a Danish citizen currently living and working in
Switzerland. He has been a successful, internationally active interim
manager for more than 15 years and has reputation as a turnaround specialist
in high-tech companies. Torben Sorensen is also active as a venture capital
manager and was CEO of a successful dental med-tech company in Sweden

Today's resolutions of the supervisory board were made in its new assembly
with Dr. Kurt Berger, Vienna. Dr. Berger is a self-employed lawyer and was
appointed by the court as of September 1, 2019 as the successor of Dr. Tomas
Kahn, who has resigned from office.

"After an application process with several candidates, the Supervisory Board
unanimously decided in favor of Torben Sorensen based on his professional
and personal skills", explains Dr. Detlef Wilke, Chairman of the Supervisory
Board. "We are convinced that Torben Sorensen has best qualifications to
lead the company into a positive operative direction, and to successfully
implement a strategic realignment," added Detlef Wilke. "We are delighted
that Torben Sorensen is taking on this responsible position and look forward
to working together with great confidence."

The leaving CEO Michael Schlenk welcomes the supervisory board's decision
and comments:"In my view the supervisory board made a good choice. I wish
Torben Sorensen every success in his challenging new task and some good luck
to lead the company and its employees into a profitable future!"

*Contact curasan AG:*
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.com

*About curasan AG:*
curasan develops, manufactures and markets biomaterials and medical devices
in the field of bone and tissue regeneration, wound healing and
osteoarthritis therapy. As a pioneer and global technology leader in the
growing field of regenerative medicine, curasan is specialized primarily on
biomimetic bone grafting materials for dental, oral/maxillofacial,
orthopedic and spinal applications, i.e. materials mimicking biological
structures. Numerous patents and a broad record of scientific publications
demonstrate the clinical success of the products and the highly innovative
strength of curasan. Dental and orthopaedic clinicians worldwide benefit
from the broad range of the premium quality and easy to use portfolio
offered by the technology leader curasan. curasan maintains its own
high-tech facilities for research, development and manufacturing of
biomaterials in Frankfurt/Main, Germany. In addition to its headquarters,
the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh,
N.C., USA. curasan's innovative products are cleared by the US Food and Drug
Administration (FDA) and many other international authorities and available
in almost 50 countries worldwide. curasan AG is a public company listed in
the General Standard at the Frankfurt Stock Exchange.

2019-09-12 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info@curasan.de
Internet: www.curasan.de
ISIN: DE000A2YPGM4
WKN: A2YPGM
Listed: Regulated Market in Frankfurt (General Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 872729

End of News DGAP News Service

872729 2019-09-12



(END) Dow Jones Newswires

September 12, 2019 05:43 ET ( 09:43 GMT)
Werbung

Das könnte Sie auch interessieren

Werbung

News-Suche

Suchbegriff:

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Die CDU-Chefin sagt der Bürokratie den Kampf an und möchte, dass es eine antragslose Auszahlung von Kinder- und Elterngeld erfolgt. Haben Sie das Gefühl, dass die Bürokratie in den letzten Jahren immer mehr zugenommen hat?
Jetzt abstimmen!
Alle Umfragen ansehen